304 results on '"Ajani, Andrew"'
Search Results
2. No-Reflow Prediction in Acute Coronary Syndrome During Percutaneous Coronary Intervention: The NORPACS Risk Score
3. Understanding long-term risk in Percutaneous Coronary Intervention (PCI) in the Australian contemporary era with a focus on defining Complex Revascularisation in High-Risk Indicated Patients (CHIP)
4. Trends in utilization and clinical outcomes with and without the use of distal filter wire embolic protection devices
5. Associations Between Dual Antiplatelet Therapy Score and Long-Term Mortality After Percutaneous Coronary Intervention: Analysis of More Than 27,000 Patients
6. The impact of stress testing to guide PCI in patients with chronic coronary disease
7. Percutaneous coronary intervention outcomes based on American College of Cardiology/American Heart Association coronary lesion classification over 14 years – Melbourne interventional group (MIG) registry
8. Real-world long-term survival after non-emergent percutaneous coronary intervention to unprotected left main coronary artery — From the Melbourne Interventional Group (MIG) registry
9. Sex Differences in Pharmacotherapy and Long-Term Outcomes in Patients With Ischaemic Heart Disease and Comorbid Left Ventricular Dysfunction
10. Cell-free DNA as a potential biomarker for acute myocardial infarction: A systematic review and meta-analysis
11. Characteristics of Radial Artery Coronary Bypass Graft Failure and Outcomes Following Subsequent Percutaneous Coronary Intervention
12. Harmonising Individual Patient Level Cardiac Registry Data Across the Asia Pacific Region—A Feasibility Study of In-Hospital Outcomes of STEMI Patients From the Asia Pacific Evaluation of Cardiovascular Therapies (ASPECT) Network
13. Prevalence and outcomes of patients with SMuRF-less acute coronary syndrome undergoing percutaneous coronary intervention
14. Role of renin–angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction
15. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
16. Trends and Real-World Safety of Patients Undergoing Percutaneous Coronary Intervention for Symptomatic Stable Ischaemic Heart Disease in Australia
17. Adverse 30-Day Clinical Outcomes and Long-Term Mortality Among Patients With Preprocedural Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
18. Long-term mortality in asymptomatic patients with stable ischemic heart disease undergoing percutaneous coronary intervention
19. Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention
20. Totally Occluded Culprit Coronary Artery in Patients with Non-ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
21. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial
22. Differences in outcome of percutaneous coronary intervention between Indigenous and non-Indigenous people in Victoria, Australia: a multicentre, prospective, observational, cohort study
23. Comparison of Outcomes of Coronary Artery Disease Treated by Percutaneous Coronary Intervention in 3 Different Age Groups (65 Years)
24. Effect of Age on Clinical Outcomes in Elderly Patients (>80 Years) Undergoing Percutaneous Coronary Intervention: Insights From a Multi-Centre Australian PCI Registry
25. Comparison of Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With Insulin-Treated Versus Non-Insulin Treated Diabetes Mellitus
26. Comparison of Long-Term Mortality in Patients With Single Coronary Narrowing and Diabetes Mellitus to That of Patients With Multivessel Coronary Narrowing Without Diabetes Mellitus
27. Outcomes of Percutaneous Coronary Intervention in Patients With Rheumatoid Arthritis
28. Cost-Effectiveness of Transcatheter Aortic Valve Intervention (TAVI) Compared to Surgical Aortic Valve Replacement (SAVR) in Low- to Intermediate-Surgical-Risk Patients
29. Multimorbidity impacts cardiovascular disease risk following percutaneous coronary intervention: latent class analysis of the Melbourne Interventional Group (MIG) registry
30. Impact of Gender and Door-to-Balloon Times on Long-Term Mortality in Patients Presenting With ST-Elevation Myocardial Infarction
31. Temporal Changes in Characteristics, Treatment and Outcomes of Heart Failure Patients Undergoing Percutaneous Coronary Intervention Findings From Melbourne Interventional Group Registry
32. One-Year Outcomes of Patients With Established Coronary Artery Disease Presenting With Acute Coronary Syndromes
33. The role of CHA2DS2-VASc score in evaluating patients with atrial fibrillation undergoing percutaneous coronary intervention
34. Heart Rate as a Predictor of Outcome Following Percutaneous Coronary Intervention
35. Real-world long-term survival after non-emergent percutaneous coronary intervention to unprotected left main coronary artery — From the Melbourne Interventional Group (MIG) registry
36. Trends and Impact of Door-to-Balloon Time on Clinical Outcomes in Patients Aged
37. Evolution of Australian Percutaneous Coronary Intervention (from the Melbourne Interventional Group [MIG] Registry)
38. Patency of conduits in patients who received internal mammary artery, radial artery and saphenous vein grafts
39. Impact of door-to-balloon time on long-term mortality in high- and low-risk patients with ST-elevation myocardial infarction
40. Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry
41. Corrigendum to ‘Temporal Change in the Remaining Life Expectancy in People Who Underwent Percutaneous Coronary Intervention’ The American Journal of Cardiology Volume 187, 15 January 2023, Pages 154-161
42. Trends in Intra-Aortic Balloon Pump Use in Cardiogenic Shock After the SHOCK-II Trial
43. Incidence, Predictors and Outcomes of Major Bleeding in Patients Following Percutaneous Coronary Interventions in Australia
44. Impact of Socioeconomic Status on Clinical Outcomes in Patients With ST-Segment–Elevation Myocardial Infarction
45. Impact of Preprocedural Diastolic Blood Pressure on Outcomes in Patients Undergoing Percutaneous Coronary Intervention.
46. Temporal Change in the Remaining Life Expectancy in People Who Underwent Percutaneous Coronary Intervention
47. Long-term survival of elderly patients undergoing percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock
48. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
49. Outcomes of thrombus aspiration during primary percutaneous coronary intervention for ST‐elevation myocardial infarction
50. Rivaroxaban in Stable Cardiovascular Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.